Navigation Links
Generic drug may improve the effectiveness of cancer nanotherapies
Date:2/2/2011

Low doses of an inexpensive, FDA-approved hypertension medication may improve the results of nanotherapeutic approaches to cancer treatment. In a report in the early edition of Proceedings of the National Academy of Sciences, Massachusetts General Hospital (MGH) investigators describe experiments showing that the generic drug losartan, by modifying the network of collagen fibers that characterizes most solid tumors, improved the effectiveness of two nanotherapeutics against several types of cancer.

"By 'normalizing' the abnormal extracellular matrix of tumors, which keeps many therapies from reaching cancer cells, losartan improved both the delivery and efficacy of cancer nanotherapies," says Rakesh Jain, PhD, director of the Steele Laboratory for Tumor Biology at MGH and senior author of the study. "We also found that this effect occurs at much lower doses than those used to manage hypertension."

Jain's team focuses on understanding how the physical and physiologic properties of tumors including their erratic blood supply and network of disorganized, fibrous tissues inhibit the delivery of anticancer drugs and on developing strategies for getting around those barriers. His team investigated whether losartan might help nanotherapeutics penetrate tumors because, in addition to its antihypertension properties, the drug is known to reduce the formation of excess fibrous tissue that can accompany heart and kidney disease and to normalize connective tissue in the genetic disorder Marfan syndrome. Although the particles that deliver nanotherapies are extremely small, they are still much larger than the extracellular spaces within most solid tumors.

In a series of experiments, the MGH investigators confirmed that low doses of losartan could inhibit the formation of collagen by tumor-associated fibroblasts in culture and within tumors implanted in mice. Losartan also improved the distribution within tumors of fluorescent nanoparticles injected either intravenously or directly into the tumors. Experiments with two nanotherapeutics liposomes containing the chemotherapy drug doxorubicin and a virus designed to infect and destroy cancer cells showed that combining each treatment with losartan significantly reduced the size or delayed the growth of implanted tumors.

"We know that losartan is safe for clinical use with minimal side effects, and since it is a generic drug, it is very inexpensive," says Yves Boucher, PhD, associate biologist in the Steele Laboratory and co-senior author of the study. "Losartan's anti-hypertensive properties could mean that patients who have hypertension in addition to cancer may simply have their prescription switched. The hypertension that can result from certain anti-angiogenic therapies may also be managed by losartan, improving the effectiveness of both anticancer therapies " Based on these data, MGH Cancer Center oncologists are planning clinical trials to translate these findings from the laboratory bench to the patient bedside.


'/>"/>

Contact: Sue McGreevey
smcgreevey@partners.org
617-724-2764
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. A New Website Series Improves Appearance and Health City by City
2. CustomerCentric Selling and Kadient Announce Joint Event in Boston to Launch Strategic Partnership for Sales Enablement and Improvement
3. Exercise Success for People Over 50: Reports of Improved Fitness, Circulation and Balance
4. NationalCreditReport.com Reminds Consumers of Ways to Improve Credit Report and Score in 2010
5. Medical Transcription Services and EHR Provider MxSecure Launches New Enhanced Website with Goal of Improved Physician Productivity
6. Retired Military Brass Support First Ladys Call to Reduce Child Obesity, Improve Nutrition
7. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
8. Medical Imaging Northwest Completes Phase I of Its Healthcare IT Integration to Maintain Patient Care Improvements
9. Nurses unite to improve cardiovascular practice
10. Behavioral therapy improves sleep and lives of patients with pain
11. Small to Mid-Sized Hospitals Turn to Orion Health to Implement Health IT Solutions for Improved Patient Care and Outcomes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2016)... ... February 07, 2016 , ... Women’s Excellence now ... the most minimally invasive approaches. , Women who have had multiple vaginal births ... factors include surgery to the pelvic floor, connective tissue disorders, and obesity. Women ...
(Date:2/7/2016)... ... February 07, 2016 , ... ... empowers employers and organizations with the tools and information to lower the costs, ... to cut the cost of providing employee healthcare benefits by as much as ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... , MEDIA ADVISORY: 5000 PERIOPERATIVE NURSES EXPECTED AT AORN SURGICAL CONFERENCE & ... nurses in the world with an estimated 5000 perioperative nurses in attendance ...
(Date:2/6/2016)... ... 06, 2016 , ... With the FCPX LUT: Summer pack from ... footage. A LUT is a Lookup Table that contains a mathematical formula for modifying ... the table. By manipulating each pixel, LUT's can change each color range differently, it ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has shown ... to reduce the frequency and level of relapse. , At the ... and Purpose,” will explore the critical tasks of the recovery phase and beyond ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... Ala. , Feb. 5, 2016  Patients in ... high intensity focused ultrasound (HIFU) therapy no longer have to ... to announce its partnership with Urology Centers of Alabama ... the newly FDA-cleared procedure for qualifying patients. ... their expertise in the treatment of prostate cancer using many ...
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
Breaking Medicine Technology: